Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AST SpaceMobile Inc (ASTS) vs CVS Health Corp (CVS) Price & Performance

AST SpaceMobile Inc
CVS Health Corp

Price performance

Price movement over the last 24 hours

Key statistics

AST SpaceMobile Inc vs CVS Health Corp — how do they compare? AST SpaceMobile Inc trades at $72 (market cap $21.90B), while CVS Health Corp trades at $104.15 (market cap $132.89B). The key difference: CVS Health Corp is far larger — about 6.1× AST SpaceMobile Inc's market cap, and CVS Health Corp pays a 2.55% dividend while AST SpaceMobile Inc pays none. Which is the better fit depends on your goals.

ASTSCVS
Market Cap
$21.90B$132.89B
Sector
MediaHealth
52-Week High
$133.09$104.81
52-Week Low
$36.91$58.75
Enterprise Value
$21.87B$199.43B
Dividend Yield
2.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AST SpaceMobile Inc

ASTS trades at $73.32, down 0.76% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported revenue of $70.92 million in 2025 but sustained a net loss of $341.94 million, missing earnings expectations for three consecutive quarters. Recent news highlights potential in defense communications via satellite technology, though competition with SpaceX remains a focal point.

The outlook is speculative with high execution risk; analyst consensus is divided with a $90.33 price target. Investment opportunity hinges on successful satellite deployment and partnership execution, but persistent losses and intense competition pose significant downside risks for shareholders.

CVS Health Corp

CVS Health trades at $104.15, up 1.3% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $2.57 exceeding expectations of $2.18. Revenue growth remains robust at $402.07B for 2025, though net margins have compressed to 0.72%. Recent dividend declarations and positive media coverage highlight the company's stable cash flow generation and market positioning.

CVS presents a compelling investment case with 84.6% analyst buy ratings and a $107.29 consensus target offering 3% upside. However, investors face risks from declining profitability margins, elevated debt levels at 25.48% debt-to-asset ratio, and competitive pressures in the healthcare sector. The stock's current valuation at 45.68 P/E requires careful monitoring of margin improvement initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AST SpaceMobile Inc

AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.

Read more on ASTS

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS